OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology  publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Biochemical Markers in Neurodegenerative Diseases

Submission Deadline: March 15, 2024 (Open) Submit Now

Guest Editor

Maria Morello, PhD, Adjunct Professor (Biography)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine Tor Vergata University, Rome, Italy

Website | E-Mail

Research Interests: the study of biochemical markers in neurodegenerative diseases as well as cytokines and vitamins in autoimmune diseases; the evaluation of cytokine and inflammatory markers in Covid

About This Topic

Several neurodegenerative diseases (such as: Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis, frontotemporal dementia and Lewy body dementia), are characterized by an irreversible, as well as progressive loss of neuronal cells of the central nervous system. The pathological manifestation of neurodegeneration depends on the brain area affected by the neuronal loss and on the type of neurons involved. Currently the measurement of some biomarkers of neurodegenerative diseases (known to date, i.e., molecules and proteins) is supportive to the clinician. However, the quantification of these biomarkers is limited: i) some of those need to be collected using invasive techniques ii) other protein biomarkers can only be identified in post-mortem tissues, but above all iii) all biomarkers known show limited specificity and sensitivity, (especially in the early stages of illness). In addition, when the brain damage is not yet irreversible, the identification of specific and new biomarkers of neurodegeneration represents a powerful tool to obtain a correct diagnosis. Such biomarkers could also be used as therapeutic target for precise pharmacological treatments.

Potential topics include: i) the measurement of classical and new neurodegenerative biomarkers (specific proteins, inflammatory molecules, and other such as miRNA) in central nervous system, peripheral tissues and biological fluids (such as urine, blood, cerebrospinal fluid, saliva or other tissues); ii) the description of innovative molecular and biochemical techniques (Cryogenic electron Microscopy, Mass Spectrometry and others) that allow the isolation, identification and characterization of biomarkers; and in conclusion iii) the analysis of these new approaches in combination with radiological imaging and clinical signs linked to the severity of the disease, permits to establish an early and a non-invasive precise diagnosis and optimize potential treatment strategies.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!